The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10232 malaria professionals are enjoying the free benefits of MalariaWorld today

Scientific Articles

Evolutionary dynamics of the immunodominant repeats of the Plasmodium vivax malaria-vaccine candidate circumsporozoite protein (CSP)

February 26, 2010 - 11:35 -- Kabogo Ndegwa
Author(s): 
Aarti Patil, Pamela Orjuela-Sánchez, Mônica da Silva-Nunes, Marcelo U. Ferreira
Reference: 
Infection, Genetics and Evolution, Volume 10, Issue 2, March 2010, Pages 298-303

To determine whether rearrangements of repeat motifs during mitotic DNA replication of parasites create significant CSP diversity under conditions of low effective meiotic recombination rates, we examined csp alleles from sympatric P. vivax isolates systematically sampled from an area of low malaria endemicity in Brazil over a period of 14 months.

Gene polymorphisms in angiotensin I converting enzyme (ACE I/D) and angiotensin II converting enzyme (ACE2 C → T) protect against cerebral malaria in Indian adults

February 26, 2010 - 11:32 -- Kabogo Ndegwa
Author(s): 
Gunanidhi Dhangadamajhi, Biranchi N. Mohapatra, Shantanu K. Kar, Manoranjan Ranjit
Reference: 
Infection, Genetics and Evolution, Volume 10, Issue 2, March 2010, Pages 337-341

To explore the hypothesis that angiotensin II may play a role in the susceptibility to cerebral malaria (CM), we performed a genetic association study of malaria patients in Orissa, India analyzing three SNPs (ACE2 C → T, iNOS C → T, eNOS Glu → Asp) and two I/D polymorphisms (ACE I/D and IL-4 B1/B2).

Country: 
Medical Condition: 

Personal View: Reducing empiricism in malaria vaccine design

February 26, 2010 - 10:59 -- Kabogo Ndegwa
Author(s): 
Vasee S Moorthy, Marie Paule Kieny
Reference: 
The Lancet Infectious Diseases, Volume 10, Issue 3, March 2010, Pages 204-211

Comparative evaluation, assay and model standardisation, greater sharing of information, collaboration and coordination between groups, and rigorous evaluation of existing datasets are steps that can be taken to enable reductions in empiricism over time.

Technology: 
Medical Condition: 
Medical Treatment: 

Opinion: The perils of PCR: can we accurately ‘correct’ antimalarial trials?

February 26, 2010 - 10:57 -- Kabogo Ndegwa
Author(s): 
Jonathan J. Juliano, Nahla Gadalla, Colin J. Sutherland, Steven R. Meshnick
Reference: 
Trends in Parasitology, Volume 26, Issue 3, March 2010, Pages 119-124

During follow-up in antimalarial drug trials, treated subjects can be newly infected. PCR correction is used to distinguish this re-infection from drug failure (recrudescence) and to adjust final drug efficacy estimates.

Update: PlasmoPredict: a gene function prediction website for Plasmodium falciparum

February 26, 2010 - 10:56 -- Kabogo Ndegwa
Author(s): 
Philip M.R. Tedder, James R. Bradford, Glenn A. McConkey, Andy J. Bulpitt, David R. Westhead
Reference: 
Trends in Parasitology, Volume 26, Issue 3, March 2010, Pages 107-110

The genome sequence of the malaria parasite Plasmodium falciparum was published in 2002 and revealed that not, vert, similar60% of its genes could not be assigned a function. Eight years later the majority of P. falciparum proteins are still of unknown function. We therefore present PlasmoPredict, an easy-to-use online gene function prediction tool that integrates a wide range of functional genomics data for P. falciparum to aid in the annotation of these genes.

Medical Condition: 

Opinion: Anticancer agents against malaria: time to revisit?

February 26, 2010 - 10:54 -- Kabogo Ndegwa
Author(s): 
Alexis Nzila, John Okombo, Ruy Perez Becker, Roma Chilengi, Trudie Lang, Tim Niehues
Reference: 
Trends in Parasitology, Volume 26, Issue 3, March 2010, Pages 125-129

In this opinion article, we examine how the toxicity of anticancer agents is just a matter of dose or ‘only dose makes the poison’, as coined in Paracelsus’ law. Thus, the opportunity exists to discover new antimalarials using the anticancer pharmacopoeia.

Medical Condition: 
Medical Treatment: 

Update: The Multilateral Initiative on Malaria: looking back and looking ahead

February 26, 2010 - 10:52 -- Kabogo Ndegwa
Author(s): 
Louis H. Miller
Reference: 
Trends in Parasitology, Volume 26, Issue 3, March 2010, Pages 110-113

I conclude that MIM is still needed today to support African scientists’ investigator-initiated research and training.

Review: Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination

February 26, 2010 - 10:45 -- Kabogo Ndegwa
Author(s): 
Timothy N.C. Wells, Jeremy N. Burrows, J. Kevin Baird
Reference: 
Trends in Parasitology, Volume 26, Issue 3, March 2010, Pages 145-151

The only clinical therapy against relapse of vivax malaria is the 8-aminoquinoline, primaquine. New, safer and more-easily administered drugs are urgently needed, and this is a crucial gap in the broader malaria-elimination agenda.

Medical Condition: 
Medical Treatment: 

Pages

Subscribe to Scientific Articles